The antitumor activity of meisoindigo against human colorectal cancer HT-29 cells in vitro and in vivo

Journal of Chemotherapy

Volumn 20, Issue 6, 2008, Pages 728-733

  Zuo, Mingxin ^a   Li, Yan ^a   Wang, Hongbo ^a   Zhou, Jianhua ^b   Li, Hongyan ^a   Liu, He ^a   Xin, Hongqi ^a   Zhang, Sen ^a   Chen, Xiaoguang ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b HARBIN UNIVERSITY OF COMMERCE   (China)

Author keywords

Antitumor activity; Colorectal cancer; GSK 3 in hibitor; Meisoindigo; Wnt signaling pathway

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; GLYCOGEN SYNTHASE KINASE 3BETA; INDIRUBIN; INDOLE DERIVATIVE; MEISOINDIGO; SERINE; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL STRAIN HT29; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 59349095464     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.6.728     Document Type: Article

References (15)

1. Ji XJ, Liu XM, Li K, Chen RH, Wang LG. Pharmacological studies of meisoindigo: absorption and mechanism of action. Biomed Environ Sci 1991; 4: 332-337.
2. Xiao Z, Hao Y, Liu B, Qian L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk Lymphoma 2002; 43(9):1763-1768.
3. Wang Y, Zhu XF, Xiao ZJ Wang HH, Zhou JM, Mei YP et al. Inducement effect of meisoindigo on apoptosis of leukemia cell Line HL-60 and its mechanism. Ai Zheng 2005; 24 (12):1464-1468.
4. Hoessel R, Leclerc S, Endicott JA, Nobel ME, Lawrie A, Tunnah P et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol. 1999; 1: 60-67.
5. Meijer L, Skaltsounis AL, Magiatis P, Ploychronopoulos P, Knockaert M, Leost M et al. GSK-3-selective inhibitors derived from tyrian purple indirubins. Chem Biol 2003; 10:1255-1266.
6. Eisenbrand G, Hippe F, Jakobs S, Muehlbeyer S. Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine. J Cancer Res Clin Oncol 2004; 130 (11): 627-635.
7. Martinez A, Castro A, Dorronsoro I, Alonso M. Glycogen synthase kinase 3 (GSK-3) Inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev 2002; 22 (4): 373-384.
8. Lustig B, Behrens J. The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 2003; 129: 199-221.
9. Behrens J. The role of the Wnt signaling pathway in colorectal tumorigenesis, Biochemical Society Transactions 2005; 33: 672-675.
10. Zhang N, Jiang Y, Zou J, Zhang B, Jin H, Wang Y et al. 3D QSAR for GSK-3p inhibition by indirubin analogues. Eur J Med Chem 2006; 41(3): 373-378.
11. Dajani R, Fraser E, Roe S. M, Young N, Good V, Die TC et al. Crystal structure of glycogen synthase kinase -3β: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 2001; 105: 721-732.
12. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004; 20: 781-810.
13. Lu D, Zhao Y, Tawatac, R, Cottam HB, Sen M,Leoni LM et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2004; 101(9): 3118-23.
14. Ougolkov AV, Billadeau DD. Targeting GSK-3: a promising approach for cancer therapy. Future Oncol 2006; 2 (1):91-100.
15. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003; 116: 1175-1186.